文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

免疫治疗的进展及双特异性抗体在癌症中的应用。

Immunotherapeutic progress and application of bispecific antibody in cancer.

机构信息

Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

出版信息

Front Immunol. 2022 Oct 20;13:1020003. doi: 10.3389/fimmu.2022.1020003. eCollection 2022.

DOI:10.3389/fimmu.2022.1020003
PMID:36341333
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9630604/
Abstract

Bispecific antibodies (bsAbs) are artificial antibodies with two distinct antigen-binding sites that can bind to different antigens or different epitopes on the same antigen. Based on a variety of technology platforms currently developed, bsAbs can exhibit different formats and mechanisms of action. The upgrading of antibody technology has promoted the development of bsAbs, which has been effectively used in the treatment of tumors. So far, 7 bsAbs have been approved for marketing in the world, and more than 200 bsAbs are in clinical and preclinical research stages. Here, we summarize the development process of bsAbs, application in tumor treatment and look forward to the challenges in future development.

摘要

双特异性抗体（bsAbs）是具有两个独特抗原结合位点的人工抗体，能够结合不同的抗原或同一抗原上的不同表位。基于目前开发的多种技术平台，bsAbs 可以表现出不同的形式和作用机制。抗体技术的升级推动了 bsAbs 的发展，使其在肿瘤治疗中得到了有效应用。迄今为止，全球已有 7 种 bsAbs 获准上市，超过 200 种 bsAbs 处于临床和临床前研究阶段。本文总结了 bsAbs 的发展历程、在肿瘤治疗中的应用，并对未来发展面临的挑战进行了展望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/564d3bbab864/fimmu-13-1020003-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/14c715d049df/fimmu-13-1020003-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/a0eab5329aab/fimmu-13-1020003-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/59fdc56ee676/fimmu-13-1020003-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/a5fc90441b28/fimmu-13-1020003-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/564d3bbab864/fimmu-13-1020003-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/14c715d049df/fimmu-13-1020003-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/a0eab5329aab/fimmu-13-1020003-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/59fdc56ee676/fimmu-13-1020003-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/a5fc90441b28/fimmu-13-1020003-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/742e/9630604/564d3bbab864/fimmu-13-1020003-g005.jpg

相似文献

[1]
Immunotherapeutic progress and application of bispecific antibody in cancer.

Front Immunol. 2022

[2]
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.

Pharmacol Ther. 2019-4-24

[3]
Bispecific Antibodies: From Research to Clinical Application.

Front Immunol. 2021

[4]
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.

Cell Mol Immunol. 2020-5

[5]
Current landscape and future directions of bispecific antibodies in cancer immunotherapy.

Front Immunol. 2022

[6]
Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.

Cancer Biol Med. 2023-3-24

[7]
Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.

Immunol Invest. 2022-11

[8]
Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.

Int J Biol Macromol. 2021-1-15

[9]
Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy.

J Immunol Res. 2019-2-11

[10]
Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.

Arch Pharm Res. 2023-3

引用本文的文献

[1]
Chitosan-Glycerol Injectable Hydrogel for Intratumoral Delivery of Macromolecules.

Gels. 2025-8-2

[2]
Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.

Antibodies (Basel). 2025-6-24

[3]
Understanding the HIV-specific T-cell response to immune checkpoint blockade: what can we learn from cancer immunotherapy?

Curr Opin HIV AIDS. 2025-9-1

[4]
Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy.

Biomolecules. 2025-4-29

[5]
Future of bNAbs in HIV Treatment.

Curr HIV/AIDS Rep. 2025-5-27

[6]
A new EGFR and c-Met bispecific NIR-II fluorescent probe for visualising colorectal cancer and metastatic lymph nodes.

EBioMedicine. 2025-5

[7]
Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer.

Cancer Biol Med. 2025-4-7

[8]
Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.

Int J Biol Sci. 2025-1-27

[9]
Quantifying antibody binding: techniques and therapeutic implications.

MAbs. 2025-12

[10]
Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies.

Biomol Ther (Seoul). 2024-11-1

本文引用的文献

[1]
Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling.

Front Oncol. 2022-9-14

[2]
Mosunetuzumab: First Approval.

Drugs. 2022-7

[3]
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).

Leukemia. 2022-5

[4]
Facile discovery of surrogate cytokine agonists.

Cell. 2022-4-14

[5]
Ozoralizumab, a Humanized Anti-TNFα NANOBODY Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG.

Front Immunol. 2022

[6]
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Cancer Discov. 2022-5-2

[7]
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

Lancet. 2022-2-19

[8]
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer.

Lung Cancer (Auckl). 2021-12-2

[9]
T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity.

Pharmaceuticals (Basel). 2021-11-17

[10]
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

J Clin Oncol. 2021-10-20

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索